Merrimack Pharmaceuticals And sanofi-aventis Initiate Enrollment in a Phase 2 Combination Study of MM-121 And …
Merrimack Pharmaceuticals And sanofi-aventis Initiate Enrollment in a Phase 2 Combination Study of MM-121 And …
Merrimack Pharmaceuticals, Inc. and sanofi-aventis announced today that the first patient has received an initial dose in a Phase 2 randomized double blind clinical study combining MM-121 with exemestane (Aromasin®) in breast cancer patients.
Read more on PharmaceuticalOnline
Categories: Metastatic Breast Cancer Tags: combination, enrollment, initiate, Merrimack, MM121, Pharmaceuticals, Phase, SanofiAventis, Study
Merrimack To Present At BIO On The Development Of MM-111, A Novel Bispecific ErbB2/ErbB3 Antibody With Potent Anti …
Merrimack To Present At BIO On The Development Of MM-111, A Novel Bispecific ErbB2/ErbB3 Antibody With Potent Anti …
Merrimack Pharmaceuticals’ MM-111 Team Leader Charlotte McDonagh, Ph.D., will discuss the development of this novel, bispecific antibody on Tuesday, May 4, at the BIO 2010 International Convention in Chicago, Illinois. Designed to specifically inhibit ErbB3 signaling in ErbB2 over-expressing cancer cells, MM-111 binds to the critical ErbB2/ErbB3 cell receptor signaling complex and disables it …
Read more on Medical News Today
Categories: Breast Cancer Tumor Tags: Anti, Antibody, Bispecific, Development, ErbB2/ErbB3, Merrimack, MM111, novel, Potent, present